Pierrel Logo

Pierrel

Global pharma company specializing in dental anesthetics and contract manufacturing services.

PRL | XMIL

Overview

Corporate Details

ISIN(s):
IT0005549644
LEI:
8156002BC7CB6E3BD403
Country:
Italy
Address:
STRADA STATALE APPIA 7 BIS, 46/48, 81043 CAPUA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pierrel is a global pharmaceutical company, established in 1948, specializing in the oral health sector. The company's core activities encompass the development, production, registration, and licensing of dental anesthetics and complementary medical devices. Its product portfolio features proprietary brands such as Orabloc®, Ubisestin™, Xylestesin™, and Mepivastesin™, which are distributed in global markets. Operating a production facility authorized by major regulatory bodies, including the EMA and FDA, Pierrel manufactures injectable drugs for its own brands and provides contract manufacturing services to the broader biopharmaceutical industry. The company focuses on delivering innovative solutions for dental professionals worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-01-24 12:25
Delisting Announcement
Pierrel S.p.A.: OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA SULLE AZION…
Italian 249.0 KB
2024-01-17 19:37
Delisting Announcement
Pierrel S.p.A.: OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA SULLE AZION…
Italian 262.6 KB
2023-12-20 20:07
Post-Annual General Meeting Information
Pierrel S.p.A.: Comunicato ai sensi dell’art. 41, co. 6 RE, emesso da PRL S.p.A…
Italian 261.4 KB
2023-12-15 21:19
Delisting Announcement
Pierrel S.p.A.: Comunicato ai sensi dell’art. 36 del RE, emesso da PRL SpA
Italian 230.9 KB
2023-12-14 20:16
Pre-Annual General Meeting Information
Pierrel S.p.A.: Comunicato ai sensi degli artt. 36 e 43 del Regolamento adottat…
Italian 227.0 KB
2023-11-29 11:28
Annual / Quarterly Financial Statement
Pierrel S.p.A.: Bilancio d'esercizio al 31.12.2022
Italian 4.9 MB
2023-11-28 21:23
M&A Activity
Pierrel S.p.A.: Comunicato ai sensi dell’art. 36 del RE - emesso da PRL S.p.A. …
Italian 242.8 KB
2023-11-24 23:43
M&A Activity
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 2 RE,emesso da PRL S.p.A.…
Italian 221.8 KB
2023-11-24 19:28
M&A Activity
Pierrel S.p.A.: IL CDA DI PIERREL APPROVA IL COMUNICATO DELL’EMITTENTE IN REL. …
Italian 256.7 KB
2023-11-22 22:55
Delisting Announcement
Pierrel S.p.A.: PRL S.p.A. OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA …
Italian 203.6 KB
2023-11-16 15:43
Post-Annual General Meeting Information
Pierrel S.p.A.: Informazioni essenziali Addendum al patto parasociale – 16 nove…
Italian 310.4 KB
2023-11-16 15:40
M&A Activity
Pierrel S.p.A.: Estratto Addendum al patto parasociale – 16 novembre 2023
Italian 1.2 MB
2023-11-15 11:03
M&A Activity
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 1, del Regolamento - AVVI…
Italian 133.7 KB
2023-10-31 17:18
Regulatory News Service
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 1,emesso da PRL S.p.A. e …
Italian 141.2 KB
2023-10-24 11:11
M&A Activity
Pierrel S.p.A.: Comunicato ai sensi dell’art. 102, comma 3, del D.Lgs. 24 febbr…
Italian 215.6 KB

Automate Your Workflow. Get a real-time feed of all Pierrel filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pierrel via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Eisai Co., Ltd. Logo
A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.
Japan 4523
Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden ELIC
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden ELN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel ENLV
Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden ERMA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea 183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea 446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden EQL
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP

Talk to a Data Expert

Have a question? We'll get back to you promptly.